Lamotrigine Tablet
NDC Package 55111-221-78
Package Information
Lamotrigine tablets is adjunctive TherapyLamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older:partial seizures primary generalized tonic-clonic (PGTC) seizuresgeneralized seizures of Lennox-Gastaut syndrome Monotherapy Lamotrigine tablets are indicated for conversion to monotherapy in adults (≥16 years of age) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets are have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. This formulation utilizes a tablet delivery system. Marketed by Dr.reddy's Laboratories Limited, this product is identified by NDC 55111-221 and is authorized under FDA application ANDA076708.
Identification & Billing
- RxCUI: 198427 - lamoTRIgine 100 MG Oral Tablet
- RxCUI: 198427 - lamotrigine 100 MG Oral Tablet
- RxCUI: 198428 - lamoTRIgine 150 MG Oral Tablet
- RxCUI: 198428 - lamotrigine 150 MG Oral Tablet
- RxCUI: 198429 - lamoTRIgine 200 MG Oral Tablet
Clinical Specifications
- Anti-epileptic Agent - [EPC] (Established Pharmacologic Class)
- Decreased Central Nervous System Disorganized Electrical Activity - [PE] (Physiologic Effect)
- Dihydrofolate Reductase Inhibitors - [MoA] (Mechanism of Action)
- Mood Stabilizer - [EPC] (Established Pharmacologic Class)
- Organic Cation Transporter 2 Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 55111 - Dr.reddy's Laboratories Limited
- 55111-221 - Lamotrigine
- 55111-221-78 - 10 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK (55111-221-79)
- 55111-221 - Lamotrigine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (55111-221). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55111-221-78 identifies a specific commercial package of 10 blister pack in 1 carton / 10 tablet in 1 blister pack (55111-221-79) of Lamotrigine, a human prescription drug labeled by Dr.reddy's Laboratories Limited. This tablet is formulated for oral use and contains lamotrigine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dr.reddy's Laboratories Limited on January 29, 2009. The current certification is valid through December 31, 2027.
How is this Dr.reddy's Laboratories Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55111022178. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.